Answers are grounded in this paper and cite their sources.
Meta-analysis compares outcomes of anti-PD-1 and anti-PD-L1 antibodies in cancer, suggesting shared mechanisms limit differentiation.
Checkpoint inhibitors that target PD‐1 or PD‐L1 have had a profound effect in a variety of cancers, both as a single therapy and in combinations. Meta‐analyses suggest that monoclonal antibodies (mAbs) targeting PD‐1 may yield better survival outcomes compared to anti‐PD‐L1 mAbs, however these conclusions are limited by a lack of direct clinical comparisons between the two classes. There is a shared hypothesis for the mechanism of action of these drugs: inhibition of the PD‐1:PD‐L1 signaling pathway through binding to either target. Using a Quantitative Systems Pharmacology (QSP) model‐based analysis, we test whether differential inhibition of PD‐1:PD‐L1 complex formation (a surrogate for inhibition of the signaling pathway) is sufficient to explain the efficacy difference between anti‐PD‐1 and anti‐PD‐L1 mAbs observed in clinical meta‐analyses. The model predicts that high levels of PD‐1:PD‐L1 complex inhibition are achieved by all the considered mAbs at their clinical dosing regimens, but it does not indicate that anti‐PD‐1 mAbs yield higher inhibition over anti‐PD‐L1s, in contrast to the meta‐analyses. Significant model parameter variability and a bootstrap sampling analysis mirroring the comparison from Duan et al. (2020) do not change this conclusion. This suggests that anti‐PD‐1 and anti‐PD‐L1 mAbs are not differentiable based on PD‐1:PD‐L1 complex inhibition alone, and that the hypothesized shared mechanism of action of the two classes of drugs is incomplete.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: